QPPV.COM KNOWLEDGE ASSESSMENT

Nemolizumab: Mechanism, Clinical Safety and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Nemolizumab: Mechanism, Clinical Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which event is specifically described as a post-marketing uncommon reaction?

Bullous pemphigoid Renal failure Myocardial infarction Severe neutropenia

Question 2 of 10 Which description most accurately characterises nemolizumab's pharmacological action?

A broad immunosuppressant that nonspecifically reduces T-cell activity A humanised IgG2 monoclonal antibody that blocks IL-31 receptor alpha A small-molecule inhibitor that directly neutralises circulating histamine A corticosteroid that suppresses epidermal inflammation

Question 3 of 10 Which statement correctly distinguishes the labelled populations for atopic dermatitis and prurigo nodularis?

Both indications are limited to adults Atopic dermatitis includes patients aged 12 years and older, whereas prurigo nodularis is indicated in adults Prurigo nodularis is indicated from age 12, whereas atopic dermatitis is limited to adults Both indications require patients to be under 90 kg

Question 4 of 10 Which traceability information is especially relevant when investigating a potential product or administration issue?

Product name, batch or lot, dose, date, injection site, storage, missed doses and device information Only the patient's preferred injection site Only the number of topical treatments used Only the date of the first clinical response

Question 5 of 10 Which factor determines the maintenance dose in the prurigo nodularis schedule described in the article?

Baseline eosinophil count Body weight, using a 90 kg threshold Severity of injection-site reactions Whether the patient uses a topical calcineurin inhibitor

Question 6 of 10 Which EU patient population is within the labelled indication for nemolizumab in atopic dermatitis?

All patients with mild atopic dermatitis from birth Patients aged 12 years and older with moderate-to-severe disease who are candidates for systemic therapy Adults with any severity of atopic dermatitis who have failed an antibiotic Children under 12 years with moderate disease requiring topical treatment

Question 7 of 10 What is the principal analytical risk of pooling atopic dermatitis and prurigo nodularis safety data without stratification?

It guarantees that the overall adverse-event rate will be higher It can obscure indication-specific or dose-related patterns because populations, schedules and relevant risk factors differ It prevents any assessment of injection-site reactions It proves that adverse events are unrelated to dose

Question 8 of 10 Which statement best describes the relevance of self-injection or caregiver administration?

Self-injection is appropriate for every patient without preparation Self-injection may be used after appropriate training when suitable, and training, handling and device issues should be recorded Self-injection eliminates the need to document injection dates and sites Caregiver administration means medication errors cannot occur

Question 9 of 10 Which finding most strongly supports assessment of a systemic hypersensitivity reaction rather than a local injection-site reaction?

Mild redness confined to the injection site Transient tenderness at the injection site without other symptoms Urticaria accompanied by periocular swelling after an injection A small bruise at the injection site several days later

Question 10 of 10 A patient with atopic dermatitis starts nemolizumab. Which regimen best reflects the schedule described in the article?

60 mg initially, then 30 mg every four weeks for 16 weeks; responders may continue with 30 mg every eight weeks 30 mg initially, then 60 mg every four weeks indefinitely 60 mg every four weeks indefinitely, regardless of response 30 mg initially, then 30 mg every 12 weeks from the beginning

QPPV.com

Nemolizumab: Mechanism, Clinical Safety and Pharmacovigilance — Knowledge Assessment

Cookie Settings